Navigation Links
CVS Caremark Industry-Leading Generic Dispensing Rate Reduces Client Traditional Drug Spend by 3.6 Percent for 2012
Date:4/11/2013

WOONSOCKET, R.I., April 11, 2013 /PRNewswire/ -- CVS Caremark (NYSE: CVS) today released its annual Insights report, which reviews drug trend and highlights key issues in pharmacy care.  In a pivotal finding, the 2012 analysis revealed that the increased availability of generics combined with CVS Caremark's industry-leading generic dispensing rate (GDR) of 77.4 percent helped reduce spending on traditional medications by 3.6 percent for the company's commercial clients (i.e., health plans and employers).

(Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO)

CVS Caremark's industry-leading GDR is the result of two key elements.  First, 2012 marked a high point in the flood of generic launches, with the estimated market value of brands that lost their patents in 2012 exceeding $35 billion.  Second, CVS Caremark worked closely with PBM clients to maximize the cost-saving opportunities posed by generics as broadly as possible, using strategies such as formulary management and step therapy plan designs to encourage the use of cost-effective generic drugs. In fact, 70 percent of CVS Caremark plan sponsors use generic step therapy or are considering implementing it in the near future.

While spending for traditional medications decreased, spending on specialty medications grew by 18.1 percent for commercial clients, becoming the main driver of overall drug trend of 0.3 percent. Specialty drugs treat more complex diseases such as multiple sclerosis, rheumatoid arthritis, hepatitis C and cancer.  Overall, specialty drugs now represent nearly 20 percent of total drug spend among CVS Caremark clients, growing by three percentage points and representing the largest increase in the past six years.

"As the generic wave begins to subside in the coming years, the impact of specialty pharmacy on client spend will only increase," said Jon Roberts , president of CVS Caremark's pharmacy benefit management business. "We know that specialty pharmacy trend is driven by the same forces – utilization, price and drug mix – as trend for more traditional drugs. Although biogenerics are not yet a factor in helping to manage costs, CVS Caremark is still able to provide a variety of solutions to help our clients effectively manage their specialty pharmacy spend while continuing to ensure access to these medications for the patients who need them."

In addition to tracking drug trends, CVS Caremark analyzed the impact of improved medication adherence for its PBM clients. "In 2012, CVS Caremark's commercial clients benefited from cost savings of more than $643 million on their overall health care spend as the result of improved medication adherence for chronic conditions," said Roberts.

The adherence cost savings were calculated using the company's proprietary Pharmacy Care Economic Model (PCEM), which enables CVS Caremark to calculate the financial value of improved pharmacy care by taking a holistic approach to reviewing adherence, gaps in care and use of generic alternatives. CVS Caremark's innovative pharmacy care programs such as Pharmacy Advisor® are succeeding in moving a significant portion of PBM members to optimal levels of medication adherence.  The savings calculated using the PCEM are due to medical cost avoidance, closing gaps in care, drug cost savings and productivity loss avoidance.

Access the full 2013 Insights Report in the publication section at the following link: http://www.cvscaremarkfyi.com/insights2013

About CVS Caremark
CVS Caremark is dedicated to helping people on their path to better health as the largest integrated pharmacy company in the United States. Through the company's more than 7,400 CVS/pharmacy stores; its leading pharmacy benefit manager serving more than 60 million plan members; and its retail health clinic system, the largest in the nation with more than 600 MinuteClinic locations, it is a market leader in mail order, retail and specialty pharmacy, retail clinics, and Medicare Part D Prescription Drug Plans.  As a pharmacy innovation company with an unmatched breadth of capabilities, CVS Caremark continually strives to improve health and lower costs by developing new approaches such as its unique Pharmacy Advisor program that helps people with chronic diseases such as diabetes obtain and stay on their medications.  Find more information about how CVS Caremark is reinventing pharmacy for better health at info.cvscaremark.com.Media Contact:Christine Cramer

Maura MoneCVS Caremark

CVS Caremark(401)770 3317

(401) 770 6351Christine.cramer@cvscaremark.com

Maura.mone@cvscaremark.com


'/>"/>
SOURCE CVS Caremark
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CVS Caremark Charitable Trust Supports Non-profits Nationwide with $2.6 Million in Funding
2. CVS Caremark Research Finds Medication Adherence Can Improve Outcomes and Reduce Costs for Patients with Coronary Artery Disease
3. CVS Caremark MinuteClinic President Discusses Primary Care Innovation at London Healthcare Conferences
4. CVS Caremark Emphasizes Commitment to Older Americans at Annual American Society on Aging Conference
5. Accordant Health Services, a CVS Caremark Company, Receives URAC Case Management Accreditation
6. CVS Caremark CEO Addresses Economic Club of Pittsburgh on Reinventing Pharmacy for Better Health
7. CVS Caremark Appoints New Chief Digital Officer to Lead Digital Innovation Team
8. CVS Caremark Encourages Heart Healthy Behavior During American Heart Month
9. CVS Caremark Corporation To Hold Fourth Quarter 2012 Conference Call
10. CVS Caremark Statement and Response to CMS Action
11. CVS Caremark Provides Strong Growth Outlook for 2013 and Beyond, Announces 38%Dividend Increase and Outlines Strategic Growth Framework
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
(Date:6/23/2016)... and INDIANAPOLIS , June ... receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is any ... scholarship winners, announced today online at www.diabetesscholars.org ... type 1 diabetes stand in the way of academic ... supported the Foundation,s scholarship program since 2012, and continues ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic ... many turn to unhealthy avenues, such as drug or alcohol abuse, as a coping ... released tools for healthy coping following a traumatic event. , Trauma sufferers tend to ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... is actively feeding the Frederick area economy by obtaining investment capital for emerging ... the past 2½ years that have already resulted in more than a million ...
Breaking Medicine News(10 mins):